Copenhagen, Denmark—In the front-line treatment of non-small cell lung cancer (NSCLC), the checkpoint inhibitor pembrolizumab improved progression-free survival (PFS) when added to carboplatin and pemetrexed, according to the results of a randomized trial. The study is representative of broad initiatives to test immunotherapies—which have already demonstrated a survival benefit in refractory metastatic NSCLC—much earlier in the course of disease.
“The response rate is